Form 4: AbbVie Director Robert J. Alpern Reports Changes in Beneficial Ownership

Director Robert J. Alpern reports acquisition of stock equivalent units in AbbVie through director fees and dividend reinvestment.

Summary

• Robert J. Alpern, a director of AbbVie Inc., filed a Form 4 with the SEC on April 02, 2025.
• The report details changes in his beneficial ownership of AbbVie securities.
• On March 31, 2025, Alpern acquired 35 stock equivalent units at a price of $209.52 per unit as director fees.
• These units are held in grantor trusts and will be paid out in cash upon retirement or at age 65.
• The balance of stock equivalent units owned following the transaction is 9,907, which includes units acquired through dividend reinvestment.
• The reporting person has direct ownership of the stock equivalent units.

Sentiment

Score: 7

Explanation: The document reflects standard insider transactions, indicating confidence in the company's performance. It is a neutral to slightly positive signal.

Positives

• The acquisition of stock equivalent units demonstrates the director's continued investment in AbbVie's future.
• Dividend reinvestment further increases the director's stake in the company.

Industry Context

Form 4 filings are standard practice for company insiders to report changes in their ownership of company securities, providing transparency to investors.

Stakeholder Impact

• The report provides transparency to shareholders regarding insider transactions.
• The director's investment in stock equivalent units aligns his interests with those of the shareholders.

Key Dates

Keywords

AbbVie, Director, Stock Equivalent Units, Beneficial Ownership, Form 4, Alpern, Dividend Reinvestment, Director Fees